nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCB1—ulcerative colitis	0.306	1	CbGaD
Afatinib—ABCG2—Sulfasalazine—ulcerative colitis	0.0614	0.241	CbGbCtD
Afatinib—ABCG2—Hydrocortisone—ulcerative colitis	0.0493	0.193	CbGbCtD
Afatinib—ABCG2—Dexamethasone—ulcerative colitis	0.0307	0.12	CbGbCtD
Afatinib—ABCB1—Methylprednisolone—ulcerative colitis	0.0292	0.115	CbGbCtD
Afatinib—ABCB1—Betamethasone—ulcerative colitis	0.019	0.0746	CbGbCtD
Afatinib—ABCB1—Prednisolone—ulcerative colitis	0.0188	0.0736	CbGbCtD
Afatinib—ABCB1—Hydrocortisone—ulcerative colitis	0.0178	0.0697	CbGbCtD
Afatinib—ABCB1—Prednisone—ulcerative colitis	0.0177	0.0695	CbGbCtD
Afatinib—ABCB1—Dexamethasone—ulcerative colitis	0.0111	0.0434	CbGbCtD
Afatinib—Vandetanib—RIPK2—ulcerative colitis	0.00562	0.794	CrCbGaD
Afatinib—BLK—lymphoid tissue—ulcerative colitis	0.00362	0.0938	CbGeAlD
Afatinib—ERBB2—epithelium—ulcerative colitis	0.00323	0.0835	CbGeAlD
Afatinib—ERBB4—epithelium—ulcerative colitis	0.00323	0.0835	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—ulcerative colitis	0.00311	0.0804	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—ulcerative colitis	0.00248	0.0643	CbGeAlD
Afatinib—ERBB2—digestive system—ulcerative colitis	0.00245	0.0635	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—ulcerative colitis	0.00239	0.0619	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—ulcerative colitis	0.00232	0.0602	CbGeAlD
Afatinib—PHKG2—liver—ulcerative colitis	0.00203	0.0526	CbGeAlD
Afatinib—ERBB2—liver—ulcerative colitis	0.00183	0.0473	CbGeAlD
Afatinib—DYRK1A—liver—ulcerative colitis	0.00176	0.0455	CbGeAlD
Afatinib—EGFR—liver—ulcerative colitis	0.00155	0.0401	CbGeAlD
Afatinib—IRAK1—liver—ulcerative colitis	0.00137	0.0354	CbGeAlD
Afatinib—LCK—liver—ulcerative colitis	0.00133	0.0345	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—ulcerative colitis	0.0013	0.0337	CbGeAlD
Afatinib—ABL1—lymphoid tissue—ulcerative colitis	0.00104	0.0269	CbGeAlD
Afatinib—ABL1—digestive system—ulcerative colitis	0.00103	0.0266	CbGeAlD
Afatinib—ABL1—liver—ulcerative colitis	0.000766	0.0198	CbGeAlD
Afatinib—ERBB2—Triamcinolone—Budesonide—ulcerative colitis	0.000611	0.0939	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Budesonide—ulcerative colitis	0.00058	0.0891	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Methylprednisolone—ulcerative colitis	0.000542	0.0832	CbGdCrCtD
Afatinib—Conjunctivitis—Mesalazine—ulcerative colitis	0.000521	0.00351	CcSEcCtD
Afatinib—Urinary tract infection—Mesalazine—ulcerative colitis	0.000521	0.00351	CcSEcCtD
Afatinib—Mental disorder—Budesonide—ulcerative colitis	0.000519	0.00349	CcSEcCtD
Afatinib—Malnutrition—Budesonide—ulcerative colitis	0.000515	0.00347	CcSEcCtD
Afatinib—Vandetanib—ALB—ulcerative colitis	0.00051	0.0721	CrCbGaD
Afatinib—Hepatobiliary disease—Mesalazine—ulcerative colitis	0.000507	0.00342	CcSEcCtD
Afatinib—Epistaxis—Mesalazine—ulcerative colitis	0.000506	0.00341	CcSEcCtD
Afatinib—Dysgeusia—Budesonide—ulcerative colitis	0.000505	0.0034	CcSEcCtD
Afatinib—Back pain—Budesonide—ulcerative colitis	0.000499	0.00336	CcSEcCtD
Afatinib—Body temperature increased—Mercaptopurine—ulcerative colitis	0.000498	0.00336	CcSEcCtD
Afatinib—Muscle spasms—Budesonide—ulcerative colitis	0.000496	0.00334	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisone—ulcerative colitis	0.000495	0.076	CbGdCrCtD
Afatinib—Gefitinib—ALB—ulcerative colitis	0.000484	0.0685	CrCbGaD
Afatinib—ABCG2—liver—ulcerative colitis	0.000483	0.0125	CbGeAlD
Afatinib—Body temperature increased—Nicotine—ulcerative colitis	0.000483	0.00325	CcSEcCtD
Afatinib—ERBB2—Exemestane—Prednisolone—ulcerative colitis	0.000483	0.0741	CbGdCrCtD
Afatinib—Mediastinal disorder—Azathioprine—ulcerative colitis	0.000476	0.00321	CcSEcCtD
Afatinib—Urinary tract disorder—Mesalazine—ulcerative colitis	0.000475	0.0032	CcSEcCtD
Afatinib—Connective tissue disorder—Mesalazine—ulcerative colitis	0.000473	0.00319	CcSEcCtD
Afatinib—Urethral disorder—Mesalazine—ulcerative colitis	0.000472	0.00318	CcSEcCtD
Afatinib—Alopecia—Azathioprine—ulcerative colitis	0.000467	0.00315	CcSEcCtD
Afatinib—Dry skin—Prednisolone—ulcerative colitis	0.000464	0.00313	CcSEcCtD
Afatinib—Gefitinib—ABCB1—ulcerative colitis	0.000462	0.0653	CrCbGaD
Afatinib—Dry skin—Hydrocortisone—ulcerative colitis	0.000454	0.00306	CcSEcCtD
Afatinib—Hypokalaemia—Hydrocortisone—ulcerative colitis	0.00045	0.00303	CcSEcCtD
Afatinib—Eye disorder—Mesalazine—ulcerative colitis	0.00045	0.00303	CcSEcCtD
Afatinib—Cough—Budesonide—ulcerative colitis	0.00045	0.00303	CcSEcCtD
Afatinib—Sepsis—Prednisone—ulcerative colitis	0.00044	0.00297	CcSEcCtD
Afatinib—Asthenia—Nicotine—ulcerative colitis	0.000438	0.00295	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Hydrocortisone—ulcerative colitis	0.000437	0.00294	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Budesonide—ulcerative colitis	0.000436	0.00294	CcSEcCtD
Afatinib—Mediastinal disorder—Mesalazine—ulcerative colitis	0.000434	0.00292	CcSEcCtD
Afatinib—Pruritus—Nicotine—ulcerative colitis	0.000432	0.00291	CcSEcCtD
Afatinib—Diarrhoea—Mercaptopurine—ulcerative colitis	0.000431	0.0029	CcSEcCtD
Afatinib—Alopecia—Mesalazine—ulcerative colitis	0.000425	0.00287	CcSEcCtD
Afatinib—Mental disorder—Mesalazine—ulcerative colitis	0.000422	0.00284	CcSEcCtD
Afatinib—ABCB1—epithelium—ulcerative colitis	0.00042	0.0109	CbGeAlD
Afatinib—Diarrhoea—Nicotine—ulcerative colitis	0.000418	0.00281	CcSEcCtD
Afatinib—Infection—Budesonide—ulcerative colitis	0.000418	0.00281	CcSEcCtD
Afatinib—Nervous system disorder—Budesonide—ulcerative colitis	0.000412	0.00278	CcSEcCtD
Afatinib—Dysgeusia—Mesalazine—ulcerative colitis	0.00041	0.00276	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Methylprednisolone—ulcerative colitis	0.00041	0.00276	CcSEcCtD
Afatinib—Skin disorder—Budesonide—ulcerative colitis	0.000409	0.00275	CcSEcCtD
Afatinib—Back pain—Mesalazine—ulcerative colitis	0.000405	0.00273	CcSEcCtD
Afatinib—Dizziness—Nicotine—ulcerative colitis	0.000404	0.00272	CcSEcCtD
Afatinib—Muscle spasms—Mesalazine—ulcerative colitis	0.000403	0.00271	CcSEcCtD
Afatinib—Vomiting—Mercaptopurine—ulcerative colitis	0.000401	0.0027	CcSEcCtD
Afatinib—Upper respiratory tract infection—Hydrocortisone—ulcerative colitis	0.000398	0.00268	CcSEcCtD
Afatinib—Rash—Mercaptopurine—ulcerative colitis	0.000397	0.00268	CcSEcCtD
Afatinib—Dermatitis—Mercaptopurine—ulcerative colitis	0.000397	0.00267	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—ulcerative colitis	0.000389	0.00262	CcSEcCtD
Afatinib—Vomiting—Nicotine—ulcerative colitis	0.000388	0.00262	CcSEcCtD
Afatinib—Dry skin—Betamethasone—ulcerative colitis	0.000388	0.00261	CcSEcCtD
Afatinib—Dry skin—Dexamethasone—ulcerative colitis	0.000388	0.00261	CcSEcCtD
Afatinib—Weight decreased—Hydrocortisone—ulcerative colitis	0.000387	0.00261	CcSEcCtD
Afatinib—Rash—Nicotine—ulcerative colitis	0.000385	0.00259	CcSEcCtD
Afatinib—Hypokalaemia—Dexamethasone—ulcerative colitis	0.000385	0.00259	CcSEcCtD
Afatinib—Hypokalaemia—Betamethasone—ulcerative colitis	0.000385	0.00259	CcSEcCtD
Afatinib—Dermatitis—Nicotine—ulcerative colitis	0.000385	0.00259	CcSEcCtD
Afatinib—Headache—Nicotine—ulcerative colitis	0.000383	0.00258	CcSEcCtD
Afatinib—Infestation—Hydrocortisone—ulcerative colitis	0.000381	0.00257	CcSEcCtD
Afatinib—Infestation NOS—Hydrocortisone—ulcerative colitis	0.000381	0.00257	CcSEcCtD
Afatinib—Insomnia—Budesonide—ulcerative colitis	0.00038	0.00256	CcSEcCtD
Afatinib—Conjunctivitis—Prednisolone—ulcerative colitis	0.00038	0.00256	CcSEcCtD
Afatinib—Dyspnoea—Budesonide—ulcerative colitis	0.000375	0.00253	CcSEcCtD
Afatinib—Nausea—Mercaptopurine—ulcerative colitis	0.000374	0.00252	CcSEcCtD
Afatinib—Upper respiratory tract infection—Triamcinolone—ulcerative colitis	0.000374	0.00252	CcSEcCtD
Afatinib—Infection—Azathioprine—ulcerative colitis	0.000373	0.00251	CcSEcCtD
Afatinib—Dyspepsia—Budesonide—ulcerative colitis	0.00037	0.00249	CcSEcCtD
Afatinib—Cough—Mesalazine—ulcerative colitis	0.000366	0.00246	CcSEcCtD
Afatinib—Decreased appetite—Budesonide—ulcerative colitis	0.000366	0.00246	CcSEcCtD
Afatinib—Skin disorder—Azathioprine—ulcerative colitis	0.000365	0.00246	CcSEcCtD
Afatinib—Gastrointestinal disorder—Budesonide—ulcerative colitis	0.000363	0.00245	CcSEcCtD
Afatinib—Nausea—Nicotine—ulcerative colitis	0.000363	0.00244	CcSEcCtD
Afatinib—Fatigue—Budesonide—ulcerative colitis	0.000363	0.00244	CcSEcCtD
Afatinib—Constipation—Budesonide—ulcerative colitis	0.00036	0.00242	CcSEcCtD
Afatinib—Infestation—Methylprednisolone—ulcerative colitis	0.000358	0.00241	CcSEcCtD
Afatinib—Infestation NOS—Methylprednisolone—ulcerative colitis	0.000358	0.00241	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—ulcerative colitis	0.000354	0.00239	CcSEcCtD
Afatinib—Conjunctivitis—Triamcinolone—ulcerative colitis	0.000349	0.00235	CcSEcCtD
Afatinib—Infection—Mesalazine—ulcerative colitis	0.00034	0.00229	CcSEcCtD
Afatinib—Epistaxis—Triamcinolone—ulcerative colitis	0.000339	0.00228	CcSEcCtD
Afatinib—Dry skin—Prednisone—ulcerative colitis	0.000338	0.00227	CcSEcCtD
Afatinib—Connective tissue disorder—Hydrocortisone—ulcerative colitis	0.000336	0.00227	CcSEcCtD
Afatinib—Nervous system disorder—Mesalazine—ulcerative colitis	0.000335	0.00226	CcSEcCtD
Afatinib—Hypokalaemia—Prednisone—ulcerative colitis	0.000335	0.00226	CcSEcCtD
Afatinib—Body temperature increased—Budesonide—ulcerative colitis	0.000333	0.00224	CcSEcCtD
Afatinib—Skin disorder—Mesalazine—ulcerative colitis	0.000332	0.00224	CcSEcCtD
Afatinib—Weight decreased—Betamethasone—ulcerative colitis	0.000331	0.00223	CcSEcCtD
Afatinib—Weight decreased—Dexamethasone—ulcerative colitis	0.000331	0.00223	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Prednisone—ulcerative colitis	0.000325	0.00219	CcSEcCtD
Afatinib—Gastrointestinal disorder—Azathioprine—ulcerative colitis	0.000324	0.00218	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—ulcerative colitis	0.000324	0.00838	CbGeAlD
Afatinib—Eye disorder—Hydrocortisone—ulcerative colitis	0.00032	0.00216	CcSEcCtD
Afatinib—ABCB1—digestive system—ulcerative colitis	0.00032	0.00828	CbGeAlD
Afatinib—Conjunctivitis—Betamethasone—ulcerative colitis	0.000317	0.00213	CcSEcCtD
Afatinib—Conjunctivitis—Dexamethasone—ulcerative colitis	0.000317	0.00213	CcSEcCtD
Afatinib—Connective tissue disorder—Methylprednisolone—ulcerative colitis	0.000316	0.00213	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Hydrocortisone—ulcerative colitis	0.000313	0.0481	CbGdCrCtD
Afatinib—Insomnia—Mesalazine—ulcerative colitis	0.000309	0.00208	CcSEcCtD
Afatinib—Dyspnoea—Mesalazine—ulcerative colitis	0.000305	0.00205	CcSEcCtD
Afatinib—Asthenia—Budesonide—ulcerative colitis	0.000302	0.00203	CcSEcCtD
Afatinib—Dyspepsia—Mesalazine—ulcerative colitis	0.000301	0.00203	CcSEcCtD
Afatinib—Eye disorder—Methylprednisolone—ulcerative colitis	0.000301	0.00202	CcSEcCtD
Afatinib—Mental disorder—Hydrocortisone—ulcerative colitis	0.0003	0.00202	CcSEcCtD
Afatinib—Malnutrition—Hydrocortisone—ulcerative colitis	0.000298	0.00201	CcSEcCtD
Afatinib—Pruritus—Budesonide—ulcerative colitis	0.000298	0.002	CcSEcCtD
Afatinib—Decreased appetite—Mesalazine—ulcerative colitis	0.000297	0.002	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Hydrocortisone—ulcerative colitis	0.000297	0.0456	CbGdCrCtD
Afatinib—Body temperature increased—Azathioprine—ulcerative colitis	0.000297	0.002	CcSEcCtD
Afatinib—Gastrointestinal disorder—Mesalazine—ulcerative colitis	0.000295	0.00199	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Methylprednisolone—ulcerative colitis	0.000295	0.0453	CbGdCrCtD
Afatinib—Fatigue—Mesalazine—ulcerative colitis	0.000295	0.00199	CcSEcCtD
Afatinib—Constipation—Mesalazine—ulcerative colitis	0.000293	0.00197	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Betamethasone—ulcerative colitis	0.000291	0.0446	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Dexamethasone—ulcerative colitis	0.000291	0.0446	CbGdCrCtD
Afatinib—Mediastinal disorder—Methylprednisolone—ulcerative colitis	0.00029	0.00195	CcSEcCtD
Afatinib—Weight decreased—Prednisone—ulcerative colitis	0.000288	0.00194	CcSEcCtD
Afatinib—Diarrhoea—Budesonide—ulcerative colitis	0.000288	0.00194	CcSEcCtD
Afatinib—Mental disorder—Methylprednisolone—ulcerative colitis	0.000282	0.0019	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Methylprednisolone—ulcerative colitis	0.00028	0.0431	CbGdCrCtD
Afatinib—Malnutrition—Methylprednisolone—ulcerative colitis	0.00028	0.00189	CcSEcCtD
Afatinib—Dizziness—Budesonide—ulcerative colitis	0.000278	0.00187	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Dexamethasone—ulcerative colitis	0.000276	0.0424	CbGdCrCtD
Afatinib—ERBB2—Desoximetasone—Betamethasone—ulcerative colitis	0.000276	0.0424	CbGdCrCtD
Afatinib—Dysgeusia—Triamcinolone—ulcerative colitis	0.000275	0.00185	CcSEcCtD
Afatinib—Eye disorder—Dexamethasone—ulcerative colitis	0.000273	0.00184	CcSEcCtD
Afatinib—Eye disorder—Betamethasone—ulcerative colitis	0.000273	0.00184	CcSEcCtD
Afatinib—Back pain—Triamcinolone—ulcerative colitis	0.000271	0.00183	CcSEcCtD
Afatinib—Body temperature increased—Mesalazine—ulcerative colitis	0.00027	0.00182	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Triamcinolone—ulcerative colitis	0.00027	0.0414	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—ulcerative colitis	0.000269	0.0414	CbGdCrCtD
Afatinib—Vomiting—Budesonide—ulcerative colitis	0.000267	0.0018	CcSEcCtD
Afatinib—Rash—Budesonide—ulcerative colitis	0.000265	0.00179	CcSEcCtD
Afatinib—Dermatitis—Budesonide—ulcerative colitis	0.000265	0.00178	CcSEcCtD
Afatinib—Headache—Budesonide—ulcerative colitis	0.000264	0.00178	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisolone—ulcerative colitis	0.000263	0.0404	CbGdCrCtD
Afatinib—Alopecia—Betamethasone—ulcerative colitis	0.000258	0.00174	CcSEcCtD
Afatinib—Alopecia—Dexamethasone—ulcerative colitis	0.000258	0.00174	CcSEcCtD
Afatinib—Diarrhoea—Azathioprine—ulcerative colitis	0.000257	0.00173	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—ulcerative colitis	0.000256	0.0393	CbGdCrCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—ulcerative colitis	0.000252	0.0017	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—ulcerative colitis	0.00025	0.00169	CcSEcCtD
Afatinib—Nausea—Budesonide—ulcerative colitis	0.00025	0.00168	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisolone—ulcerative colitis	0.00025	0.0384	CbGdCrCtD
Afatinib—Dizziness—Azathioprine—ulcerative colitis	0.000248	0.00167	CcSEcCtD
Afatinib—Asthenia—Mesalazine—ulcerative colitis	0.000245	0.00165	CcSEcCtD
Afatinib—Cough—Triamcinolone—ulcerative colitis	0.000245	0.00165	CcSEcCtD
Afatinib—Pruritus—Mesalazine—ulcerative colitis	0.000242	0.00163	CcSEcCtD
Afatinib—Infection—Hydrocortisone—ulcerative colitis	0.000242	0.00163	CcSEcCtD
Afatinib—Vomiting—Azathioprine—ulcerative colitis	0.000239	0.00161	CcSEcCtD
Afatinib—Nervous system disorder—Hydrocortisone—ulcerative colitis	0.000239	0.00161	CcSEcCtD
Afatinib—ABCB1—liver—ulcerative colitis	0.000238	0.00617	CbGeAlD
Afatinib—Eye disorder—Prednisone—ulcerative colitis	0.000238	0.0016	CcSEcCtD
Afatinib—Rash—Azathioprine—ulcerative colitis	0.000237	0.0016	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ulcerative colitis	0.000237	0.00159	CcSEcCtD
Afatinib—Dermatitis—Azathioprine—ulcerative colitis	0.000237	0.00159	CcSEcCtD
Afatinib—Skin disorder—Hydrocortisone—ulcerative colitis	0.000236	0.00159	CcSEcCtD
Afatinib—Headache—Azathioprine—ulcerative colitis	0.000235	0.00158	CcSEcCtD
Afatinib—Diarrhoea—Mesalazine—ulcerative colitis	0.000234	0.00158	CcSEcCtD
Afatinib—Infection—Triamcinolone—ulcerative colitis	0.000228	0.00153	CcSEcCtD
Afatinib—Infection—Methylprednisolone—ulcerative colitis	0.000227	0.00153	CcSEcCtD
Afatinib—Dizziness—Mesalazine—ulcerative colitis	0.000226	0.00152	CcSEcCtD
Afatinib—Insomnia—Prednisolone—ulcerative colitis	0.000225	0.00152	CcSEcCtD
Afatinib—Alopecia—Prednisone—ulcerative colitis	0.000225	0.00152	CcSEcCtD
Afatinib—Nervous system disorder—Methylprednisolone—ulcerative colitis	0.000224	0.00151	CcSEcCtD
Afatinib—Mental disorder—Prednisone—ulcerative colitis	0.000223	0.0015	CcSEcCtD
Afatinib—Nausea—Azathioprine—ulcerative colitis	0.000223	0.0015	CcSEcCtD
Afatinib—Skin disorder—Methylprednisolone—ulcerative colitis	0.000222	0.0015	CcSEcCtD
Afatinib—Malnutrition—Prednisone—ulcerative colitis	0.000222	0.00149	CcSEcCtD
Afatinib—Insomnia—Hydrocortisone—ulcerative colitis	0.00022	0.00148	CcSEcCtD
Afatinib—Vomiting—Mesalazine—ulcerative colitis	0.000217	0.00147	CcSEcCtD
Afatinib—Rash—Mesalazine—ulcerative colitis	0.000216	0.00145	CcSEcCtD
Afatinib—Dermatitis—Mesalazine—ulcerative colitis	0.000215	0.00145	CcSEcCtD
Afatinib—Headache—Mesalazine—ulcerative colitis	0.000214	0.00144	CcSEcCtD
Afatinib—Dyspepsia—Hydrocortisone—ulcerative colitis	0.000214	0.00144	CcSEcCtD
Afatinib—Decreased appetite—Hydrocortisone—ulcerative colitis	0.000211	0.00142	CcSEcCtD
Afatinib—Gastrointestinal disorder—Hydrocortisone—ulcerative colitis	0.00021	0.00141	CcSEcCtD
Afatinib—Fatigue—Hydrocortisone—ulcerative colitis	0.00021	0.00141	CcSEcCtD
Afatinib—Insomnia—Triamcinolone—ulcerative colitis	0.000207	0.0014	CcSEcCtD
Afatinib—Insomnia—Methylprednisolone—ulcerative colitis	0.000207	0.00139	CcSEcCtD
Afatinib—Infection—Betamethasone—ulcerative colitis	0.000206	0.00139	CcSEcCtD
Afatinib—Infection—Dexamethasone—ulcerative colitis	0.000206	0.00139	CcSEcCtD
Afatinib—Dyspnoea—Triamcinolone—ulcerative colitis	0.000204	0.00138	CcSEcCtD
Afatinib—Nervous system disorder—Dexamethasone—ulcerative colitis	0.000204	0.00137	CcSEcCtD
Afatinib—Nervous system disorder—Betamethasone—ulcerative colitis	0.000204	0.00137	CcSEcCtD
Afatinib—Nausea—Mesalazine—ulcerative colitis	0.000203	0.00137	CcSEcCtD
Afatinib—Dyspepsia—Triamcinolone—ulcerative colitis	0.000202	0.00136	CcSEcCtD
Afatinib—Dyspepsia—Methylprednisolone—ulcerative colitis	0.000201	0.00136	CcSEcCtD
Afatinib—Fatigue—Triamcinolone—ulcerative colitis	0.000197	0.00133	CcSEcCtD
Afatinib—Fatigue—Methylprednisolone—ulcerative colitis	0.000197	0.00133	CcSEcCtD
Afatinib—Body temperature increased—Hydrocortisone—ulcerative colitis	0.000192	0.0013	CcSEcCtD
Afatinib—Insomnia—Dexamethasone—ulcerative colitis	0.000188	0.00127	CcSEcCtD
Afatinib—Insomnia—Betamethasone—ulcerative colitis	0.000188	0.00127	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ulcerative colitis	0.000187	0.00126	CcSEcCtD
Afatinib—Dyspepsia—Betamethasone—ulcerative colitis	0.000183	0.00123	CcSEcCtD
Afatinib—Dyspepsia—Dexamethasone—ulcerative colitis	0.000183	0.00123	CcSEcCtD
Afatinib—Body temperature increased—Triamcinolone—ulcerative colitis	0.000181	0.00122	CcSEcCtD
Afatinib—Decreased appetite—Dexamethasone—ulcerative colitis	0.000181	0.00122	CcSEcCtD
Afatinib—Decreased appetite—Betamethasone—ulcerative colitis	0.000181	0.00122	CcSEcCtD
Afatinib—Infection—Prednisone—ulcerative colitis	0.00018	0.00121	CcSEcCtD
Afatinib—Gastrointestinal disorder—Dexamethasone—ulcerative colitis	0.000179	0.00121	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betamethasone—ulcerative colitis	0.000179	0.00121	CcSEcCtD
Afatinib—Fatigue—Dexamethasone—ulcerative colitis	0.000179	0.00121	CcSEcCtD
Afatinib—Fatigue—Betamethasone—ulcerative colitis	0.000179	0.00121	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—ulcerative colitis	0.000177	0.0012	CcSEcCtD
Afatinib—Skin disorder—Prednisone—ulcerative colitis	0.000176	0.00118	CcSEcCtD
Afatinib—Asthenia—Hydrocortisone—ulcerative colitis	0.000175	0.00118	CcSEcCtD
Afatinib—ERBB2—Levonorgestrel—Hydrocortisone—ulcerative colitis	0.000174	0.0267	CbGdCrCtD
Afatinib—Pruritus—Hydrocortisone—ulcerative colitis	0.000172	0.00116	CcSEcCtD
Afatinib—Diarrhoea—Hydrocortisone—ulcerative colitis	0.000166	0.00112	CcSEcCtD
Afatinib—Dizziness—Prednisolone—ulcerative colitis	0.000165	0.00111	CcSEcCtD
Afatinib—Asthenia—Triamcinolone—ulcerative colitis	0.000164	0.00111	CcSEcCtD
Afatinib—Body temperature increased—Dexamethasone—ulcerative colitis	0.000164	0.00111	CcSEcCtD
Afatinib—Body temperature increased—Betamethasone—ulcerative colitis	0.000164	0.00111	CcSEcCtD
Afatinib—Asthenia—Methylprednisolone—ulcerative colitis	0.000164	0.0011	CcSEcCtD
Afatinib—Insomnia—Prednisone—ulcerative colitis	0.000164	0.0011	CcSEcCtD
Afatinib—Pruritus—Triamcinolone—ulcerative colitis	0.000162	0.00109	CcSEcCtD
Afatinib—Pruritus—Methylprednisolone—ulcerative colitis	0.000162	0.00109	CcSEcCtD
Afatinib—Dizziness—Hydrocortisone—ulcerative colitis	0.000161	0.00108	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—ulcerative colitis	0.000159	0.00107	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—ulcerative colitis	0.000157	0.00106	CcSEcCtD
Afatinib—Rash—Prednisolone—ulcerative colitis	0.000157	0.00106	CcSEcCtD
Afatinib—Dermatitis—Prednisolone—ulcerative colitis	0.000157	0.00106	CcSEcCtD
Afatinib—Diarrhoea—Methylprednisolone—ulcerative colitis	0.000156	0.00105	CcSEcCtD
Afatinib—Fatigue—Prednisone—ulcerative colitis	0.000156	0.00105	CcSEcCtD
Afatinib—Headache—Prednisolone—ulcerative colitis	0.000156	0.00105	CcSEcCtD
Afatinib—Constipation—Prednisone—ulcerative colitis	0.000155	0.00104	CcSEcCtD
Afatinib—Vomiting—Hydrocortisone—ulcerative colitis	0.000155	0.00104	CcSEcCtD
Afatinib—Rash—Hydrocortisone—ulcerative colitis	0.000153	0.00103	CcSEcCtD
Afatinib—Dermatitis—Hydrocortisone—ulcerative colitis	0.000153	0.00103	CcSEcCtD
Afatinib—Headache—Hydrocortisone—ulcerative colitis	0.000152	0.00103	CcSEcCtD
Afatinib—Dizziness—Triamcinolone—ulcerative colitis	0.000151	0.00102	CcSEcCtD
Afatinib—Dizziness—Methylprednisolone—ulcerative colitis	0.000151	0.00102	CcSEcCtD
Afatinib—Asthenia—Betamethasone—ulcerative colitis	0.000149	0.001	CcSEcCtD
Afatinib—Asthenia—Dexamethasone—ulcerative colitis	0.000149	0.001	CcSEcCtD
Afatinib—Nausea—Prednisolone—ulcerative colitis	0.000148	0.000997	CcSEcCtD
Afatinib—Pruritus—Betamethasone—ulcerative colitis	0.000147	0.00099	CcSEcCtD
Afatinib—Pruritus—Dexamethasone—ulcerative colitis	0.000147	0.00099	CcSEcCtD
Afatinib—Vomiting—Triamcinolone—ulcerative colitis	0.000146	0.000981	CcSEcCtD
Afatinib—Vomiting—Methylprednisolone—ulcerative colitis	0.000145	0.000979	CcSEcCtD
Afatinib—Nausea—Hydrocortisone—ulcerative colitis	0.000144	0.000973	CcSEcCtD
Afatinib—Rash—Triamcinolone—ulcerative colitis	0.000144	0.000973	CcSEcCtD
Afatinib—Dermatitis—Triamcinolone—ulcerative colitis	0.000144	0.000972	CcSEcCtD
Afatinib—Rash—Methylprednisolone—ulcerative colitis	0.000144	0.000971	CcSEcCtD
Afatinib—Dermatitis—Methylprednisolone—ulcerative colitis	0.000144	0.00097	CcSEcCtD
Afatinib—Headache—Triamcinolone—ulcerative colitis	0.000143	0.000967	CcSEcCtD
Afatinib—Headache—Methylprednisolone—ulcerative colitis	0.000143	0.000964	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—ulcerative colitis	0.000143	0.000964	CcSEcCtD
Afatinib—Diarrhoea—Dexamethasone—ulcerative colitis	0.000142	0.000958	CcSEcCtD
Afatinib—Diarrhoea—Betamethasone—ulcerative colitis	0.000142	0.000958	CcSEcCtD
Afatinib—Dizziness—Dexamethasone—ulcerative colitis	0.000137	0.000926	CcSEcCtD
Afatinib—Dizziness—Betamethasone—ulcerative colitis	0.000137	0.000926	CcSEcCtD
Afatinib—Nausea—Triamcinolone—ulcerative colitis	0.000136	0.000916	CcSEcCtD
Afatinib—Nausea—Methylprednisolone—ulcerative colitis	0.000136	0.000914	CcSEcCtD
Afatinib—Vomiting—Dexamethasone—ulcerative colitis	0.000132	0.00089	CcSEcCtD
Afatinib—Vomiting—Betamethasone—ulcerative colitis	0.000132	0.00089	CcSEcCtD
Afatinib—Rash—Betamethasone—ulcerative colitis	0.000131	0.000883	CcSEcCtD
Afatinib—Rash—Dexamethasone—ulcerative colitis	0.000131	0.000883	CcSEcCtD
Afatinib—Dermatitis—Dexamethasone—ulcerative colitis	0.000131	0.000882	CcSEcCtD
Afatinib—Dermatitis—Betamethasone—ulcerative colitis	0.000131	0.000882	CcSEcCtD
Afatinib—Headache—Betamethasone—ulcerative colitis	0.00013	0.000877	CcSEcCtD
Afatinib—Headache—Dexamethasone—ulcerative colitis	0.00013	0.000877	CcSEcCtD
Afatinib—Asthenia—Prednisone—ulcerative colitis	0.00013	0.000875	CcSEcCtD
Afatinib—Pruritus—Prednisone—ulcerative colitis	0.000128	0.000863	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—ulcerative colitis	0.000124	0.000834	CcSEcCtD
Afatinib—Nausea—Betamethasone—ulcerative colitis	0.000123	0.000832	CcSEcCtD
Afatinib—Nausea—Dexamethasone—ulcerative colitis	0.000123	0.000832	CcSEcCtD
Afatinib—Dizziness—Prednisone—ulcerative colitis	0.00012	0.000806	CcSEcCtD
Afatinib—Vomiting—Prednisone—ulcerative colitis	0.000115	0.000775	CcSEcCtD
Afatinib—Rash—Prednisone—ulcerative colitis	0.000114	0.000769	CcSEcCtD
Afatinib—Dermatitis—Prednisone—ulcerative colitis	0.000114	0.000768	CcSEcCtD
Afatinib—Headache—Prednisone—ulcerative colitis	0.000113	0.000764	CcSEcCtD
Afatinib—Nausea—Prednisone—ulcerative colitis	0.000108	0.000724	CcSEcCtD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—ulcerative colitis	2.32e-05	9.73e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD4—ulcerative colitis	2.32e-05	9.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—ICAM1—ulcerative colitis	2.32e-05	9.71e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IFNG—ulcerative colitis	2.31e-05	9.68e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—JAK2—ulcerative colitis	2.3e-05	9.61e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD4—ulcerative colitis	2.29e-05	9.59e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NOD2—ulcerative colitis	2.29e-05	9.58e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—RELA—ulcerative colitis	2.28e-05	9.55e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—VCAM1—ulcerative colitis	2.28e-05	9.54e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD14—ulcerative colitis	2.27e-05	9.52e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DQA1—ulcerative colitis	2.27e-05	9.51e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—RELA—ulcerative colitis	2.26e-05	9.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—JAK2—ulcerative colitis	2.26e-05	9.47e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDH1—ulcerative colitis	2.26e-05	9.47e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP9—ulcerative colitis	2.26e-05	9.45e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ADCY5—ulcerative colitis	2.26e-05	9.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCR2—ulcerative colitis	2.26e-05	9.45e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NFKB1—ulcerative colitis	2.23e-05	9.35e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—CD4—ulcerative colitis	2.23e-05	9.35e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—JAK2—ulcerative colitis	2.21e-05	9.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR6—ulcerative colitis	2.2e-05	9.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADRB2—ulcerative colitis	2.2e-05	9.2e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—VCAM1—ulcerative colitis	2.19e-05	9.19e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DQA1—ulcerative colitis	2.19e-05	9.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—ulcerative colitis	2.19e-05	9.16e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDH1—ulcerative colitis	2.18e-05	9.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1B—ulcerative colitis	2.18e-05	9.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD4—ulcerative colitis	2.18e-05	9.11e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL2—ulcerative colitis	2.17e-05	9.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—ulcerative colitis	2.16e-05	9.05e-05	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—ulcerative colitis	2.16e-05	9.03e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1B—ulcerative colitis	2.14e-05	8.98e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD4—ulcerative colitis	2.14e-05	8.98e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL2—ulcerative colitis	2.14e-05	8.94e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS1—ulcerative colitis	2.13e-05	8.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—ulcerative colitis	2.13e-05	8.91e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR6—ulcerative colitis	2.12e-05	8.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—ADCY5—ulcerative colitis	2.11e-05	8.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAML2—ulcerative colitis	2.09e-05	8.74e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—JAK2—ulcerative colitis	2.06e-05	8.64e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—ulcerative colitis	2.06e-05	8.64e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—ulcerative colitis	2.06e-05	8.63e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL2—ulcerative colitis	2.05e-05	8.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDH1—ulcerative colitis	2.05e-05	8.59e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NFKB1—ulcerative colitis	2.03e-05	8.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAML2—ulcerative colitis	2.01e-05	8.42e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—STAT3—ulcerative colitis	2.01e-05	8.4e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NFKB1—ulcerative colitis	2e-05	8.38e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—RELA—ulcerative colitis	2e-05	8.37e-05	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—ALB—ulcerative colitis	1.99e-05	8.34e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—JAK2—ulcerative colitis	1.99e-05	8.33e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CRP—ulcerative colitis	1.97e-05	8.27e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NFKB1—ulcerative colitis	1.97e-05	8.26e-05	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—ulcerative colitis	1.96e-05	8.23e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—ulcerative colitis	1.96e-05	8.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTGER4—ulcerative colitis	1.94e-05	8.11e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—ulcerative colitis	1.93e-05	8.08e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ADCY5—ulcerative colitis	1.93e-05	8.07e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IL2—ulcerative colitis	1.93e-05	8.07e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—RELA—ulcerative colitis	1.93e-05	8.07e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—NFKB1—ulcerative colitis	1.92e-05	8.06e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—RELA—ulcerative colitis	1.92e-05	8.04e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CALM3—ulcerative colitis	1.92e-05	8.03e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NFKB1—ulcerative colitis	1.91e-05	7.99e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—TLR4—ulcerative colitis	1.89e-05	7.93e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-DRB1—ulcerative colitis	1.89e-05	7.92e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—ulcerative colitis	1.88e-05	7.89e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—ulcerative colitis	1.88e-05	7.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTGER4—ulcerative colitis	1.87e-05	7.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADCY5—ulcerative colitis	1.86e-05	7.81e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TGFB1—ulcerative colitis	1.86e-05	7.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ADCY5—ulcerative colitis	1.86e-05	7.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—ulcerative colitis	1.85e-05	7.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—RELA—ulcerative colitis	1.85e-05	7.74e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TGFB1—ulcerative colitis	1.82e-05	7.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—STAT3—ulcerative colitis	1.82e-05	7.64e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—ulcerative colitis	1.82e-05	7.61e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ICAM1—ulcerative colitis	1.81e-05	7.6e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—ulcerative colitis	1.81e-05	7.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—JAK2—ulcerative colitis	1.8e-05	7.53e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—ulcerative colitis	1.8e-05	7.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—ulcerative colitis	1.79e-05	7.49e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ADCY5—ulcerative colitis	1.78e-05	7.45e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GHRL—ulcerative colitis	1.77e-05	7.43e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—ulcerative colitis	1.76e-05	7.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—RELA—ulcerative colitis	1.74e-05	7.29e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—ulcerative colitis	1.74e-05	7.27e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—ulcerative colitis	1.73e-05	7.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CALM3—ulcerative colitis	1.72e-05	7.19e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ulcerative colitis	1.72e-05	7.19e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ADCY5—ulcerative colitis	1.72e-05	7.18e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—ulcerative colitis	1.71e-05	7.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GHRL—ulcerative colitis	1.71e-05	7.16e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—ulcerative colitis	1.7e-05	7.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RIPK2—ulcerative colitis	1.69e-05	7.09e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CRP—ulcerative colitis	1.69e-05	7.06e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NFKB1—ulcerative colitis	1.69e-05	7.06e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—ulcerative colitis	1.68e-05	7.06e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—ulcerative colitis	1.68e-05	7.03e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—ulcerative colitis	1.66e-05	6.95e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CALM3—ulcerative colitis	1.66e-05	6.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RIPK2—ulcerative colitis	1.63e-05	6.83e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CRP—ulcerative colitis	1.63e-05	6.81e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NFKB1—ulcerative colitis	1.62e-05	6.8e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NFKB1—ulcerative colitis	1.62e-05	6.78e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—TLR4—ulcerative colitis	1.62e-05	6.77e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-DRB1—ulcerative colitis	1.62e-05	6.76e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—JAK2—ulcerative colitis	1.61e-05	6.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ADCY5—ulcerative colitis	1.61e-05	6.73e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—ulcerative colitis	1.6e-05	6.72e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ulcerative colitis	1.6e-05	6.71e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TGFB1—ulcerative colitis	1.59e-05	6.66e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—JAK2—ulcerative colitis	1.58e-05	6.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—ulcerative colitis	1.58e-05	6.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—ulcerative colitis	1.57e-05	6.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—ulcerative colitis	1.57e-05	6.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—TGFB1—ulcerative colitis	1.56e-05	6.54e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NFKB1—ulcerative colitis	1.56e-05	6.53e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—TLR4—ulcerative colitis	1.56e-05	6.53e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—RELA—ulcerative colitis	1.56e-05	6.52e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-DRB1—ulcerative colitis	1.56e-05	6.52e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ICAM1—ulcerative colitis	1.55e-05	6.49e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—TGFB1—ulcerative colitis	1.54e-05	6.44e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—RELA—ulcerative colitis	1.53e-05	6.42e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TGFB1—ulcerative colitis	1.5e-05	6.29e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—ulcerative colitis	1.5e-05	6.29e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ICAM1—ulcerative colitis	1.49e-05	6.26e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCB1—ulcerative colitis	1.49e-05	6.25e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—ulcerative colitis	1.48e-05	6.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADRB2—ulcerative colitis	1.47e-05	6.15e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NFKB1—ulcerative colitis	1.47e-05	6.15e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—ulcerative colitis	1.47e-05	6.14e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—ulcerative colitis	1.44e-05	6.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRB2—ulcerative colitis	1.41e-05	5.93e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ulcerative colitis	1.41e-05	5.92e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JAK2—ulcerative colitis	1.41e-05	5.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—ulcerative colitis	1.4e-05	5.87e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—ulcerative colitis	1.4e-05	5.87e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ADCY5—ulcerative colitis	1.39e-05	5.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—ulcerative colitis	1.38e-05	5.78e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—ulcerative colitis	1.38e-05	5.78e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—ulcerative colitis	1.37e-05	5.74e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—RELA—ulcerative colitis	1.36e-05	5.7e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—ulcerative colitis	1.33e-05	5.58e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—ulcerative colitis	1.33e-05	5.56e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—ulcerative colitis	1.32e-05	5.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—ulcerative colitis	1.32e-05	5.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—JAK2—ulcerative colitis	1.32e-05	5.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKB1—ulcerative colitis	1.31e-05	5.5e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—ulcerative colitis	1.31e-05	5.47e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKB1—ulcerative colitis	1.29e-05	5.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—ulcerative colitis	1.27e-05	5.34e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—ulcerative colitis	1.26e-05	5.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADCY5—ulcerative colitis	1.25e-05	5.22e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—ulcerative colitis	1.24e-05	5.18e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—ulcerative colitis	1.24e-05	5.18e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—ulcerative colitis	1.23e-05	5.16e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—ulcerative colitis	1.23e-05	5.14e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—ulcerative colitis	1.21e-05	5.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JAK2—ulcerative colitis	1.2e-05	5.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADCY5—ulcerative colitis	1.2e-05	5.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—ulcerative colitis	1.2e-05	5.03e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—ulcerative colitis	1.2e-05	5.02e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—ulcerative colitis	1.18e-05	4.94e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—ulcerative colitis	1.18e-05	4.94e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—ulcerative colitis	1.18e-05	4.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RELA—ulcerative colitis	1.16e-05	4.87e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—ulcerative colitis	1.16e-05	4.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JAK2—ulcerative colitis	1.16e-05	4.87e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—ulcerative colitis	1.16e-05	4.85e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JAK2—ulcerative colitis	1.16e-05	4.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS1—ulcerative colitis	1.15e-05	4.82e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKB1—ulcerative colitis	1.15e-05	4.81e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—ulcerative colitis	1.15e-05	4.8e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—ulcerative colitis	1.14e-05	4.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—ulcerative colitis	1.14e-05	4.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RELA—ulcerative colitis	1.13e-05	4.71e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RELA—ulcerative colitis	1.12e-05	4.7e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—JAK2—ulcerative colitis	1.11e-05	4.65e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—ulcerative colitis	1.1e-05	4.6e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—ulcerative colitis	1.09e-05	4.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—ulcerative colitis	1.08e-05	4.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—ulcerative colitis	1.08e-05	4.51e-05	CbGpPWpGaD
Afatinib—LCK—Disease—JAK2—ulcerative colitis	1.07e-05	4.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—ulcerative colitis	1.06e-05	4.44e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—ulcerative colitis	1.06e-05	4.43e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—ulcerative colitis	1.05e-05	4.41e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—ulcerative colitis	1.05e-05	4.41e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—ulcerative colitis	1.05e-05	4.39e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—ulcerative colitis	1.04e-05	4.37e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—ulcerative colitis	1.04e-05	4.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CALM3—ulcerative colitis	1.04e-05	4.34e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—ulcerative colitis	1.03e-05	4.32e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—ulcerative colitis	1.02e-05	4.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—ulcerative colitis	1.01e-05	4.25e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—ulcerative colitis	1.01e-05	4.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—ulcerative colitis	1.01e-05	4.24e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—ulcerative colitis	1.01e-05	4.23e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—ulcerative colitis	1.01e-05	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—ulcerative colitis	9.82e-06	4.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—ulcerative colitis	9.59e-06	4.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—ulcerative colitis	9.49e-06	3.97e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—ulcerative colitis	9.46e-06	3.96e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—ulcerative colitis	9.33e-06	3.91e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—ulcerative colitis	9.21e-06	3.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—ulcerative colitis	9e-06	3.77e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—ulcerative colitis	8.87e-06	3.71e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—ulcerative colitis	8.82e-06	3.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—ulcerative colitis	8.53e-06	3.57e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—ulcerative colitis	8.5e-06	3.56e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—ulcerative colitis	8.24e-06	3.45e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—ulcerative colitis	8.16e-06	3.42e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—ulcerative colitis	8.14e-06	3.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—ulcerative colitis	8.12e-06	3.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—ulcerative colitis	7.91e-06	3.31e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—ulcerative colitis	7.85e-06	3.29e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JAK2—ulcerative colitis	7.77e-06	3.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—ulcerative colitis	7.55e-06	3.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RELA—ulcerative colitis	7.53e-06	3.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADCY5—ulcerative colitis	7.52e-06	3.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JAK2—ulcerative colitis	7.49e-06	3.14e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—ulcerative colitis	7.27e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RELA—ulcerative colitis	7.25e-06	3.04e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—ulcerative colitis	7.21e-06	3.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—ulcerative colitis	7.09e-06	2.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—ulcerative colitis	6.83e-06	2.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—ulcerative colitis	6.78e-06	2.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—ulcerative colitis	6.74e-06	2.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—ulcerative colitis	6.53e-06	2.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—ulcerative colitis	6.51e-06	2.73e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—ulcerative colitis	6.41e-06	2.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—ulcerative colitis	6.35e-06	2.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—ulcerative colitis	6.18e-06	2.59e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—ulcerative colitis	6.16e-06	2.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—ulcerative colitis	6.12e-06	2.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—ulcerative colitis	5.96e-06	2.49e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—ulcerative colitis	5.94e-06	2.49e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—ulcerative colitis	5.7e-06	2.39e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—ulcerative colitis	5.69e-06	2.38e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—ulcerative colitis	5.61e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—ulcerative colitis	5.5e-06	2.3e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—ulcerative colitis	5.48e-06	2.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—ulcerative colitis	5.29e-06	2.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—ulcerative colitis	5.09e-06	2.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—ulcerative colitis	5.04e-06	2.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—ulcerative colitis	4.41e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—ulcerative colitis	4.35e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—ulcerative colitis	4.19e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—ulcerative colitis	3.98e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—ulcerative colitis	3.84e-06	1.61e-05	CbGpPWpGaD
